| |NOVEMBER 20248PRICE DRIVES CARDIAC GROWTH IN INDIA'S TOP 10 PHARMA THERAPIESThe US investments mark the initial phase of significant actions aimed at supporting AstraZeneca's goal of reaching $80 billion in overall revenue by 2030, as outlined in May of this year. The essential aspect of the approach is hastening the company's growth in the US Market. The US represents AstraZeneca's biggest market, accounting for 44 percent of its overall revenue.AstraZeneca, a worldwide, science-driven biopharmaceutical firm, declares a $3.5 billion capital investment in the United States aimed at enhancing the company's research and manufacturing presence by the conclusion of 2026. This entails $2 billion in fresh investments generating over a thousand new, high-skilled positions that support the expansion of the US economy.AstraZeneca's growing presence in the US encompasses, among other things: a cutting-edge R&D center in Kendall Square, Cambridge, Massachusetts; a next-gen biologics manufacturing plant in Maryland; cell therapy production capabilities on both the West and East Coasts; and specialized manufacturing in Texas.Pascal Soriot, chief executive officer, AstraZeneca said: "Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation." POAmong the leading 10 therapies that account for over 90 percent of the Indian pharmaceutical market, price was the key factor in the expansion of the cardiac sector. The anti-hypertensive medications, comprising nearly 50 percent of the cardiac sector, are facing flat volume growth. Lipid-lowering medications and platelet aggregation inhibitors have demonstrated a relatively greater increase to enhance the cardiac sector.In the anti-infective category, antibacterials, accounting for nearly 87 percent, have reduced the volumes. In contrast, antifungals have increased in quantity.Antacids, making up nearly 40 percent of the gastro category, have experienced a decline in sales volume, while laxatives, probiotics, anti-infectives, and anti-diarrheal products have demonstrated volume increases. "These are the factors that have increased the volume growth, while the antacids are responsible for reducing the segment's growth," Sapale stated.In the anti-diabetes sector, the combinations of oral anti-diabetics have evidenced a decline in volume growth, whereas significant growth is attributed to new product launches, as numerous items have expired patents, according to Pharmarack data. POTOP STORIESASTRAZENECA'S US INVESTMENTS PROPEL $80 BILLION REVENUE GOAL BY 2030
< Page 7 | Page 9 >